What is Cryopyrin-associated periodic syndrome

Cryopyrin-associated periodic syndrome (CAPS) is a group of rare, lifelong autoinflammatory conditions caused by genetic mutations that lead to overproduction of the protein interleukin-1 beta, resulting in recurring episodes of systemic inflammation. These syndromes cause symptoms ranging from skin rashes and joint pain to fever and, if untreated, potentially serious long-term complications like hearing loss or organ damage.

What are the three main subtypes of Cryopyrin-associated periodic syndrome?

Cryopyrin-associated periodic syndrome exists on a clinical spectrum defined by three overlapping conditions, all linked to the NLRP3 gene. These subtypes represent varying degrees of disease severity:

• Familial Cold Autoinflammatory Syndrome (FCAS): The mildest form, typically triggered by exposure to cold temperatures, leading to hives, fever, and joint pain.


• Muckle-Wells Syndrome (MWS): A moderate form characterized by intermittent hives, joint pain, and a significant risk of sensorineural hearing loss and amyloidosis (the buildup of abnormal proteins in organs).


• Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA): The most severe form, often present from birth, causing chronic hives, severe joint overgrowth, neurological inflammation, and vision issues.

What causes Cryopyrin-associated periodic syndrome?

The underlying mechanism of Cryopyrin-associated periodic syndrome is a mutation in the NLRP3 gene. This gene provides instructions for making a protein called cryopyrin, which is a key component of the "inflammasome." When this protein is mutated, the inflammasome becomes hyperactive, causing the body to produce excessive amounts of the inflammatory messenger interleukin-1 beta (IL-1β). This constant, systemic inflammation is what drives the characteristic symptoms seen in patients within our DiseaseMaps community and beyond.

Who is affected by Cryopyrin-associated periodic syndrome?

Cryopyrin-associated periodic syndrome is exceptionally rare, with an estimated prevalence of approximately 1 in 360,000 to 1 in 1,000,000 people worldwide. Because it is a genetic condition, symptoms often begin in infancy or early childhood, though milder forms like FCAS may not be fully recognized until later. There is no known predilection for specific geographic regions, genders, or ethnic groups; it affects individuals globally. Currently, 32 people with Cryopyrin-associated periodic syndrome have joined the DiseaseMaps.org community to share their experiences and support one another.

How is this condition different from other inflammatory diseases?

Unlike autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues, Cryopyrin-associated periodic syndrome is an autoinflammatory disorder. This means the innate immune system is "turned on" without a clear external trigger like an infection. Key distinguishing features include the rapid onset of "cold-induced" symptoms in FCAS and the specific progression of hearing loss and bone abnormalities in MWS and NOMID.

Next steps

• Consult a rheumatologist or immunologist who specializes in autoinflammatory diseases to discuss genetic testing.


• Connect with the 32 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Ask your specialist about IL-1 inhibitor therapies, which have revolutionized the management of Cryopyrin-associated periodic syndrome.


• Review resources from the Autoinflammatory Alliance to stay updated on current clinical trials.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• Orphanet: Cryopyrin-associated periodic syndrome (ORPHA:99960)


• NIH Genetic and Rare Diseases Information Center (GARD): Cryopyrin-associated periodic syndrome


• OMIM (Online Mendelian Inheritance in Man): NLRP3-related autoinflammatory disorders (#120100)


• Autoinflammatory Alliance: Patient-centered resources for CAPS